Rimas J. Orentas

14.3k total citations · 4 hit papers
120 papers, 8.2k citations indexed

About

Rimas J. Orentas is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Rimas J. Orentas has authored 120 papers receiving a total of 8.2k indexed citations (citations by other indexed papers that have themselves been cited), including 93 papers in Oncology, 58 papers in Immunology and 31 papers in Molecular Biology. Recurrent topics in Rimas J. Orentas's work include CAR-T cell therapy research (80 papers), Virus-based gene therapy research (26 papers) and Immune Cell Function and Interaction (26 papers). Rimas J. Orentas is often cited by papers focused on CAR-T cell therapy research (80 papers), Virus-based gene therapy research (26 papers) and Immune Cell Function and Interaction (26 papers). Rimas J. Orentas collaborates with scholars based in United States, Germany and Canada. Rimas J. Orentas's co-authors include Crystal L. Mackall, James E. K. Hildreth, Terry J. Fry, Waleed Haso, Maryalice Stetler‐Stevenson, Constance M. Yuan, Alan S. Wayne, Nirali N. Shah, Adrienne H. Long and Yongzhi Cui and has published in prestigious journals such as Science, The Lancet and Journal of Clinical Investigation.

In The Last Decade

Rimas J. Orentas

118 papers receiving 8.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

2014 2.2k citations Yongzhi Cui, Rimas J. Orentas et al. profile →
4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors

2015 1.3k citations Adrienne H. Long, Jillian Smith et al. Nature Medicine profile →
Anti-CD22–chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia

2012 440 citations Dimiter S. Dimitrov, Rimas J. Orentas et al. Blood profile →
Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial

2020 318 citations Nirav N. Shah, Bryon D. Johnson et al. Nature Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Rimas J. Orentas United States	34	6.6k	2.9k	2.2k	2.0k	1.9k	120	8.2k
Simon F. Lacey United States	50	11.9k 1.8×	4.5k 1.5×	3.9k 1.8×	3.6k 1.8×	3.3k 1.7×	157	15.0k
Yolanda D. Mahnke United States	19	4.4k 0.7×	2.6k 0.9×	1.7k 0.8×	1.2k 0.6×	1.1k 0.6×	32	6.4k
Michael Kalos United States	39	11.7k 1.8×	6.0k 2.1×	4.9k 2.2×	4.1k 2.1×	2.8k 1.5×	97	15.5k
Richard A. Morgan United States	44	4.8k 0.7×	2.8k 1.0×	2.7k 1.2×	2.5k 1.3×	877 0.5×	112	7.4k
Stephen Gottschalk United States	64	9.4k 1.4×	4.7k 1.6×	3.0k 1.4×	3.1k 1.6×	2.1k 1.1×	256	12.2k
Steven A. Feldman United States	36	9.6k 1.5×	4.7k 1.6×	3.1k 1.4×	3.0k 1.5×	2.3k 1.2×	87	11.4k
Zhaohui Zheng United States	17	5.6k 0.9×	2.1k 0.7×	1.8k 0.8×	1.7k 0.9×	1.5k 0.8×	32	6.5k
Marcela V. Maus United States	59	10.1k 1.5×	4.9k 1.7×	5.0k 2.3×	3.4k 1.8×	3.5k 1.8×	207	14.0k
Crystal L. Mackall United States	50	9.7k 1.5×	4.9k 1.7×	3.6k 1.6×	2.5k 1.3×	2.8k 1.5×	154	12.9k
Chiara Bonini Italy	48	5.8k 0.9×	4.0k 1.4×	3.6k 1.7×	3.3k 1.7×	1.1k 0.6×	180	10.7k

Countries citing papers authored by Rimas J. Orentas

Since Specialization

Citations

This map shows the geographic impact of Rimas J. Orentas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rimas J. Orentas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rimas J. Orentas more than expected).

Fields of papers citing papers by Rimas J. Orentas

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rimas J. Orentas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rimas J. Orentas. The network helps show where Rimas J. Orentas may publish in the future.

Co-authorship network of co-authors of Rimas J. Orentas

This figure shows the co-authorship network connecting the top 25 collaborators of Rimas J. Orentas. A scholar is included among the top collaborators of Rimas J. Orentas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rimas J. Orentas. Rimas J. Orentas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Pinto, Navin, Catherine M. Albert, Mallory Taylor, et al.. (2024). STRIvE-02: A First-in-Human Phase I Study of Systemically Administered B7-H3 Chimeric Antigen Receptor T Cells for Patients With Relapsed/Refractory Solid Tumors. Journal of Clinical Oncology. 42(35). 4163–4172. 14 indexed citations

Lautz, Jonathan D., Joshua A. Gustafson, Ashley Wilson, et al.. (2024). Differential protein-protein interactions underlie signaling mediated by the TCR and a 4-1BB domain–containing CAR. Science Signaling. 17(826). eadd4671–eadd4671. 4 indexed citations

Louella, Michael, et al.. (2024). Nothing about us without us: Advocacy and engagement in genetic medicine. Science Translational Medicine. 16(746). eadn2401–eadn2401. 3 indexed citations

Xiong, Ying, et al.. (2023). 320 CAR-T cell manufacturing from fresh whole blood facilitates point-of-care therapeutic cell production. SHILAP Revista de lepidopterología. A364–A364. 2 indexed citations

Sullivan, Peter M., Wei Li, Virginia J. Hoglund, et al.. (2022). FGFR4-Targeted Chimeric Antigen Receptors Combined with Anti-Myeloid Polypharmacy Effectively Treat Orthotopic Rhabdomyosarcoma. Molecular Cancer Therapeutics. 21(10). 1608–1621. 13 indexed citations

Adair, Jennifer E., Lois Bayigga, Rimas J. Orentas, et al.. (2022). Place-of-care manufacturing of gene therapies. The Lancet Haematology. 9(11). e807–e808. 4 indexed citations

Summers, Corinne, Colleen Annesley, Jason K. Yokoyama, et al.. (2021). CD22 CAR Optimization for Improved in-Human Activity Following Inadequate CD22 CAR Activity in Phase 1 Clinical Trial PLAT-04. Blood. 138(Supplement 1). 403–403. 4 indexed citations

Shah, Nirav N., Bryon D. Johnson, Dina Schneider, et al.. (2020). Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. Nature Medicine. 26(10). 1569–1575. 318 indexed citations breakdown →

Finney, Olivia, Hannah Brakke, Stephanie Rawlings-Rhea, et al.. (2019). CD19 CAR T cell product and disease attributes predict leukemia remission durability. Journal of Clinical Investigation. 129(5). 2123–2132. 244 indexed citations

10.

Orentas, Rimas J., Sivasish Sindiri, Christine Duris, et al.. (2017). Paired Expression Analysis of Tumor Cell Surface Antigens. Frontiers in Oncology. 7. 173–173. 13 indexed citations

11.

Long, Adrienne H., Steven L. Highfill, Yongzhi Cui, et al.. (2016). Reduction of MDSCs with All-trans Retinoic Acid Improves CAR Therapy Efficacy for Sarcomas. Cancer Immunology Research. 4(10). 869–880. 258 indexed citations

12.

Zhu, Fenlu, Nirav N. Shah, Huiqing Xu, et al.. (2016). CAR-T Cell Production Using the Clinimacs® Prodigy System. Blood. 128(22). 5724–5724. 14 indexed citations

13.

Highfill, Steven L., Adrienne H. Long, Rimas J. Orentas, & Crystal L. Mackall. (2013). Neutralization of murine myeloid-derived suppressor cells enhances the efficacy of a chimeric antigen receptor T-cells directed against pediatric solid tumors. Journal for ImmunoTherapy of Cancer. 1(S1). 3 indexed citations

14.

Kohler, M. Eric, William Hallett, Qingrong Chen, et al.. (2010). Early expression of stem cell-associated genes within the CD8 compartment after treatment with a tumor vaccine. Cellular Immunology. 265(1). 65–73. 4 indexed citations

15.

Saad, Ehab, Barbara A. Bresnahan, Eric P. Cohen, et al.. (2008). Successful Treatment of BK Viremia Using Reduction in Immunosuppression Without Antiviral Therapy. Transplantation. 85(6). 850–854. 83 indexed citations

16.

Zhou, Qiang, Xiaocai Yan, Jill A. Gershan, Rimas J. Orentas, & Bryon D. Johnson. (2008). Expression of Macrophage Migration Inhibitory Factor by Neuroblastoma Leads to the Inhibition of Antitumor T Cell Reactivity In Vivo. The Journal of Immunology. 181(3). 1877–1886. 31 indexed citations

17.

Rosenblum, Michael D., Edit Olasz, Bryon D. Johnson, et al.. (2003). CD200 is a novel p53-target gene involved in apoptosis-associated immune tolerance. Blood. 103(7). 2691–2698. 67 indexed citations

18.

Orentas, Rimas J., et al.. (2003). Retroviral Transfer of T‐Cell Receptor Genes Produces Cells with a Broad Range of Lytic Activity. Scandinavian Journal of Immunology. 58(1). 33–42. 10 indexed citations

19.

Orentas, Rimas J., et al.. (1998). Feasibility of Cellular Adoptive Immunotherapy for Epstein-Barr Virus-Associated Lymphomas Using Haploidentical Donors. Journal of Hematotherapy. 7(3). 257–261. 29 indexed citations

20.

Orentas, Rimas J. & James E. K. Hildreth. (1993). Association of Host Cell Surface Adhesion Receptors and Other Membrane Proteins with HIV and SIV. AIDS Research and Human Retroviruses. 9(11). 1157–1165. 172 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact